175 related articles for article (PubMed ID: 38784991)
1. Metformin: Therapeutic profile in the treatment of type 2 diabetes.
Bailey CJ
Diabetes Obes Metab; 2024 May; ():. PubMed ID: 38784991
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
4. Metformin: historical overview.
Bailey CJ
Diabetologia; 2017 Sep; 60(9):1566-1576. PubMed ID: 28776081
[TBL] [Abstract][Full Text] [Related]
5. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.
Dunn CJ; Peters DH
Drugs; 1995 May; 49(5):721-49. PubMed ID: 7601013
[TBL] [Abstract][Full Text] [Related]
6. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
[TBL] [Abstract][Full Text] [Related]
7. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
Scheen AJ
Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of
Shin NR; Gu N; Choi HS; Kim H
Am J Physiol Endocrinol Metab; 2020 Jan; 318(1):E52-E61. PubMed ID: 31770016
[TBL] [Abstract][Full Text] [Related]
9. Glucose-lowering treatment of type 2 diabetes. Part II--Glucose-lowering drugs after metformin: a choice based largely on adverse effects.
Prescrire Int; 2015 May; 24(160):130-5. PubMed ID: 26034806
[TBL] [Abstract][Full Text] [Related]
10. EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
Rohde U
Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808040
[TBL] [Abstract][Full Text] [Related]
11. Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.
Scheen AJ
Drug Saf; 2005 Jul; 28(7):601-631. PubMed ID: 27722966
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
[TBL] [Abstract][Full Text] [Related]
13. Metformin and exercise effects on postprandial insulin sensitivity and glucose kinetics in pre-diabetic and diabetic adults.
Moreno-Cabañas A; Morales-Palomo F; Alvarez-Jimenez L; Mora-Gonzalez D; Ortega JF; Mora-Rodriguez R
Am J Physiol Endocrinol Metab; 2023 Oct; 325(4):E310-E324. PubMed ID: 37584610
[TBL] [Abstract][Full Text] [Related]
14. Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D).
Das AK; Kalra S; Tiwaskar M; Bajaj S; Seshadri K; Chowdhury S; Sahay R; Indurkar S; Unnikrishnan AG; Phadke U; Pareek A; Purkait I
J Assoc Physicians India; 2019 Dec; 67(12):65-74. PubMed ID: 31801334
[TBL] [Abstract][Full Text] [Related]
15. From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management.
Pani A; Gironi I; Di Vieste G; Mion E; Bertuzzi F; Pintaudi B
Int J Endocrinol; 2020; 2020():6276187. PubMed ID: 32587614
[TBL] [Abstract][Full Text] [Related]
16. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone and pioglitazone: new preparations. Two new oral antidiabetics both poorly assessed.
Prescrire Int; 2002 Dec; 11(62):170-6. PubMed ID: 12469695
[TBL] [Abstract][Full Text] [Related]
18. The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial.
Guardado-Mendoza R; Salazar-López SS; Álvarez-Canales M; Farfán-Vázquez D; Martínez-López YE; Jiménez-Ceja LM; Suárez-Pérez EL; Angulo-Romero F; Evia-Viscarra ML; Montes de Oca-Loyola ML; Durán-Pérez EG; Folli F; Aguilar-García A
Metabolism; 2020 Mar; 104():154054. PubMed ID: 31887309
[TBL] [Abstract][Full Text] [Related]
19. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.
Bailey CJ
Diabetes Obes Metab; 2005 Nov; 7(6):675-91. PubMed ID: 16219011
[TBL] [Abstract][Full Text] [Related]
20. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.
Setter SM; Iltz JL; Thams J; Campbell RK
Clin Ther; 2003 Dec; 25(12):2991-3026. PubMed ID: 14749143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
